Taurus Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Taurus Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-116,873	Closed	-$21.5M	–	97
2021 Q2	$21.5M	Sell	116,873 -5,440	-4%	-$934K	2.24%	17
2021 Q1	$18.7M	Sell	122,313 -2,920	-2%	-$452K	2.16%	20
2020 Q4	$19.6M	Sell	125,233 -24,325	-16%	-$3.13M	2.34%	17
2020 Q3	$17.1M	Sell	149,558 -210	-0.1%	-$22.7K	2.12%	20
2020 Q2	$16.8M	Sell	149,768 -875	-0.6%	-$92.9K	2.33%	17
2020 Q1	$13.5M	Buy	150,643 +17,975	+14%	+$1.76M	2.24%	20
2019 Q4	$14.3M	Sell	132,668 -47,342	-26%	-$5.06M	1.87%	23
2019 Q3	$17.6M	Buy	180,010 +30,625	+21%	+$3.45M	2.51%	17
2019 Q2	$19.6M	Buy	149,385 +46,794	+46%	+$6.03M	2.67%	15
2019 Q1	$13.9M	Sell	102,591 -30,200	-23%	-$3.76M	1.94%	23
2018 Q4	$12.9M	Buy	132,791 +5,735	+5%	+$678K	2.07%	18
2018 Q3	$17.7M	Buy	127,056 +20,500	+19%	+$2.57M	2.39%	14
2018 Q2	$13.2M	Buy	106,556 +985	+0.9%	+$115K	1.93%	20
2018 Q1	$11.8M	Buy	105,571 +1,615	+2%	+$193K	1.77%	26
2017 Q4	$12.4M	Buy	103,956 +85,456	+462%	+$10.4M	1.83%	26
2017 Q3	$2.6M	Hold	18,500	–	–	0.4%	52
2017 Q2	$2.25M	Buy	+18,500	New	+$2.15M	0.35%	54

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Taurus Asset Management's ALXN Position: Q3 2021 in Review

Taurus Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 116,873 shares — an estimated $21.5M sold.

Taurus Asset Management first reported a position in ALXN in Q2 2017 and held it in 17 quarters. The position peaked at $21.5M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Taurus Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Taurus Asset Management sold 116,873 Alexion Pharmaceuticals shares in Q3 2021, an estimated $21.5M.
Taurus Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 17 quarters.
Taurus Asset Management's Alexion Pharmaceuticals position peaked at $21.5M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Taurus Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.